The four studies showed no statistically significant difference in the incidence of at least one AE(s), drug-related AE(s), serious AE(s), hypoglycaemia or UTI between the combination therapy and SGLT2 inhibitor monotherapy (Table 3). Here, SLC5A2 is linked to bacterial urinary tract infection.